Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Omeros Corp (OMER)

Omeros Corp (OMER)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Omeros Corp 201 ELLIOT AVENUE WEST SEATTLE WA 98119 USA

www.omeros.com Employees: 198 P: 206-676-5000 F: 206-676-5005

Description:

Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders.

Key Statistics

Overview:

Market Capitalization, $K 391,163
Enterprise Value, $K 597,213
Shares Outstanding, K 57,950
Annual Sales, $ 0 K
Annual Net Income, $ -117,810 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -56,040 K
EBIT, $ -186,110 K
EBITDA, $ -185,190 K
60-Month Beta 1.47
% of Insider Shareholders 12.30%
% of Institutional Shareholders 48.79%
Float, K 50,822
% Float 87.70%
Short Volume Ratio 0.37

Growth:

1-Year Return 347.02%
3-Year Return -14.34%
5-Year Return -53.38%
5-Year Revenue Growth -100.00%
5-Year Earnings Growth -25.68%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.64 on 11/13/24
Next Earnings Date N/A
Earnings Per Share ttm -3.31
EPS Growth vs. Prev Qtr 42.86%
EPS Growth vs. Prev Year 21.95%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

OMER Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -49.92%
Profit Margin % 0.00%
Debt/Equity -1.54
Price/Sales N/A
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -2.15
Interest Coverage -4.67
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar